Received: 20 February 2020; Published on-line: 24 June 2020

Prospects of up-to-date antioxidants in the treatment of chronic eye diseases

O.P. Vitovska,1 L.D. Pichkur2

1Bogomolets National Medical University; Kyiv (Ukraine)

2Romodanov Neurosurgery Institute, NAMS of Ukraine; Kyiv (Ukraine)

E-mail: vo.visiondep@gmail.com

TO CITE THIS ARTICLE: Vitovska O.P., Pichkur L.D. Prospects of up-to-date antioxidants in the treatment of chronic eye diseases. J.ophthalmol.(Ukraine).2020;3:42-46.  http://doi.org/10.31288/oftalmolzh202034246

According to the World Health Organization (WHO), about 285 million people are visually impaired, and, of those, around 39 million are blind and 246 million have low vision. About 90% of the world's visually impaired people live in low-income settings while 82% of people living with blindness are aged 50 and above; this age group represents 20% of the world's population. 

Age-related macular degeneration (AMD), glaucoma, cataract and diabetic retinopathy are the most common causes of legal blindness and visual impairment in Ukraine, and, today, the role of free radicals in the development of these disorders is indisputable. Astaxanthin is a powerful antioxidant, more effective than lutein or zeaxanthin. Since astaxanthin has a beneficial molecular structure and multifaceted mechanism of action, is highly bioavailable and capable of crossing the blood brain barrier, it might be promising in the treatment of chronic incapacitating disorders such as glaucoma, diabetic retinopathy and AMD.

Keywords:  oxidative stress, AMD, glaucoma, diabetic retinopathy, antioxidants, astaxanthin



1.Ackland P, Resnikoff S, Bourne R. World blindness and visual impairment: despite many successes, the problem is growing. World blindness and visual impairment: despite many successes, the problem is growing. Community Eye Health. 2017;30(100):71–3.

2.World Health Organization. Blindness and Vision Impairment. [(accessed on 14 June 2019)];Available online:  https://www.who.int/news-room/fact-sheets/detail/blindness-and-visual-im....

3.Vitovska OP. [Health promotion strategy in ophthalmology]. Russkii meditsinckii zhurnal. Klinicheskaia odtalmologiia. Glaukoma. 2013;3:88–92. Russian.

4.Chader GJ, Taylor A. Preface: The Aging Eye: Normal Changes, Age-Related Diseases, and Sight-Saving Approaches. Invest Ophthalmol Vis Sci. 2013 Dec 13;54(14):ORSF1-4.

Crossref   PubMed

5.Li JQ, Welchowski T, Schmid M. Retinal diseases in Europe: prevalence, incidence and healthcare needs. European Society of Retina Specialists (EURETINA). 2017; 1–28. Available online:  http://www.euretina.org/downloads/EURETINA_Retinal_Diseases.pdf 

6.Vitovska OP, Vasiuta VA. [Pathways for improving medical care for patients with optic nerve atrophy]. Skhidnoievropeiskyi zhurnal gromadskogo zdorovia. 2015;1(26):58–9. Ukrainian.

7.Vitovska OP, Alifanova TA, Poveshchenko IuL. [Epidemiological aspects of primary disability caused by glaucoma in Ukraine]. Oftalmologiia. 2016;2(4):16–26. Russian. 

8.Vitovska OP, Vasiuta VA. [Analysis of the dynamics of prevalence of optic nerve atrophy in Ukraine]. Visnyk naukovykh doslidzhen. 2015;3:72–5. Ukrainian.

9.Polumbryk M, Ivanov S, Polumbryk O. Antioxidants in food systems. Mechanism of action. Ukr J Food Sci. 2013;1:15—40.

10.Carocho M, Ferreira I.C.F.R. A review on antioxidants, prooxidants and related controversy: natural and synthetic compounds, screening and analysis methodologies and future perspectives. Food Chem Toxicol. 2013 Jan;51:15-25. 

Crossref   PubMed

11.Reznikov AG, Polumbryk OM, Balion IaG, Polumbryk MO. [Pro- and anti-oxidative systems and pathological processes in the human body]. Visnyk NAN Ukrainy. 2014;10:17-29. Ukrainian.


12.Britton G. [The Biochemistry of Natural Pigments]. Moscow: Mir; 1986. Russian.

13.Kishimoto Y, Tani M, Uto-Kondo H, Iizuka M et al. Astaxanthin suppresses scavenger receptor expression and matrix metalloproteinase activity in macrophages. Eur J Nutr. 2010; 49: 119–26. 

Crossref   PubMed

14.Hussein G, Goto, H, Oda, S, Sankawa, U et al. Antihypertensive  potential and mechanism of action of astaxanthin: III. Antioxidant and histopathological effects in spontaneously hypertensive rats. Biol Pharm Bull. 2006; 29:684–8.

Crossref   PubMed

15.Ranga Rao A, Raghunath Reddy RL, Baskaran V, Sarada R, Ravishankar GA. Characterization of microalgal carotenoids by mass spectrometry and their bioavailability and antioxidant properties elucidated in rat model. J Agric Food Chem. 2010 Aug 11;58(15):8553-9.

Crossref   PubMed

16.Bohn T. Bioavailability of non-provitamin A carotenoids. Curr Nutr Food Sci. 2008;4:240–58.


17.Miki W. Biological functions and activities of animal carotenoids. Pure Appl Chem. 1991;63:141–6.


18.Palozza P, Krinsky NI. Astaxanthin and canthaxanthin are potent antioxidants in a membrane model. Arch Biochem Biophys. 1992 Sep;297(2):291-5.


19.Nishigaki I, Rajendran P, Venugopal R, Ekambaram G et al. Cytoprotective role of astaxanthin against glycated protein/iron chelate-induced toxicity in human umbilical vein endothelial cells. Phytother Res. 2010 Jan;24(1):54-9.

Crossref   PubMed

20.Papas AM. Antioxidant Status, Diet, Nutrition, and Health. Washington, DC: CRC Press; 1999. 

21.Greene L. Asthma and oxidant stress: Nutritional, environmental, and genetic risk factors. J Am Coll Nutr. 1995 Aug;14(4):317-24. Crossref   PubMed

22.Higuera-Ciapara I, F?lix-Valenzuela L, Goycoolea FM. Astaxanthin: a review of its chemistry and applications. Crit Rev Food Sci Nutr. 2006; 46(2):185–96. Crossref   PubMed

23.Hussein G, Sankawa U, Goto H, Matsumoto K, Watanabe H. Astaxanthin, a carotenoid with potential in human health and nutrition. J Nat Prod. 2006 Mar;69(3):443-9.Crossref   PubMed 

24.Nagaki Y, Mihara M, Tsukahara H, Ono S. The supplementation effect of astaxanthin on accommodation and asthenopia. J Clin Ther Med. 2006; 22:41–54. 

25.Liao JH, Chen CS, Maher TJ, Liu CY et al. Astaxanthin interacts with selenite and attenuates selenite-induced cataractogenesis. Chem Res Toxicol. 2009 Mar 16;22(3):518-25.Crossref   PubMed

26.Izumi-Nagai K, Nagai N, Ohgami K, Satofuka S, Ozawa Y, Tsubora K et al. Inhibition of choroidal neovascularization with an anti-inflammatory carotenoid astaxanthin. Invest Ophthalmol Vis Sci. 2008 Apr;49(4):1679-85.

Crossref   PubMed

27.Wu TH, Liao JH, Hou WC, Huang FY, Maher TJ, Hu CC. Astaxanthin protects against oxidative stress and calcium-induced porcine lens protein degradation. J Agric Food Chem. 2006 Mar 22;54(6):2418-23. 

Crossref   PubMed

28.Nakajima Y, Inokuchi Y, Shimazawa M, Otsubo K, Ishibashi T, Hara H. Astaxanthin, a dietary carotenoid, protects retinal cells against oxidative stress in vitro and in mice in vivo. J Pharm Pharmacol. 2008 Oct;60(10):1365-74.

Crossref   PubMed 

29.Cort A, Ozturk N, Akpinar D, Unal M, Yucel G, Ciftcioglu A, et al. Suppressive effect of astaxanthin on retinal injury induced by elevated intraocular pressure. Regul Toxicol Pharmacol. 2010 Oct;58(1):121-30.

Crossref   PubMed

30.Otton R, Marin DP, Bolin AP, Santos RDe C, Polotow TG, Sampaio SC, et al. Astaxanthin ameliorates the redox imbalance in lymphocytes of experimental diabetic rats. Chem Biol Interact. 2010 Aug 5;186(3):306-15.

Crossref   PubMed

31.Nishigaki I, Rajendran P, Venugopal R, Ekambaram G, Sakthisekaran D, Nishigaki Y. Cytoprotective role of astaxanthin against glycated protein/iron chelate-induced toxicity in human umbilical vein endothelial cells. Phytother Res. 2010 Jan;24(1):54-9.

Crossref   PubMed

32.Hussein G, Nakagawa T, Goto H, Shimada Y, Matsumoto K, Sankawa U, et al. Astaxanthin ameliorates features of metabolic syndrome in SHR/NDmcr-cp. Life Sci. 2007 Jan 16;80(6):522-9.

Crossref   PubMed  

33.Chan KC, Mong MC, Yin AC. Antioxidative and anti-inflammatory neuroprotective effects of astaxanthin and canthaxanthin in nerve growth factor differentiated PC12 cells. J Food Sci. 2009 Sep;74(7):H225-31.

Crossref   PubMed 

34.Liu XB, Shibata T, Hisaka S, Osawa T. Astaxanthin inhibits reactive oxygen species-mediated cellular toxicity in dopaminergic SH-SY5Y cells via mitochondria-targeted protective mechanism. Brain Res. 2009 Feb 13;1254:18-27.

Crossref   PubMed 


The paper was supported by 'Valartin Pharma'